Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Roche and AbbVie Face Setback in Venclexta Trial for Myelodysplastic Syndromes

Roche and AbbVie announced on Monday that their phase 3 trial of Venclexta in patients with higher-risk myelodysplastic syndromes (MDS) failed to meet its primary endpoint of overall survival. This latest setback adds to a series of challenges the companies have faced in expanding indications for their blockbuster blood cancer treatment.

NoahAI News6/17/2025

Lark Health Launches AI-Powered Platform to Manage GLP-1 Costs

Lark Health, a digital healthcare company, has unveiled LarkVantage, an artificial intelligence-enabled platform designed to manage costs associated with GLP-1 medications. This innovative tool aims to streamline the utilization review process for these increasingly popular drugs, addressing a growing challenge in the healthcare industry.

NoahAI News6/17/2025

FDA Faces Further Consolidation as Delays Continue to Plague Drug Reviews

The U.S. Food and Drug Administration (FDA) is considering additional consolidation measures amid ongoing delays in drug application reviews, according to an internal email from FDA Commissioner Marty Makary. This move comes on the heels of recent layoffs and organizational changes that have already impacted the agency's operations.

NoahAI News6/16/2025

Former 23andMe CEO Anne Wojcicki Secures Company's Future with $305M Winning Bid

In a dramatic turn of events for the embattled genetic testing company 23andMe, former CEO Anne Wojcicki has emerged victorious in a high-stakes bankruptcy auction. Her non-profit organization, TTAM Research Institute, placed a winning bid of $305 million, outpacing pharmaceutical giant Regeneron's previous offer of $256 million.

NoahAI News6/16/2025

Gilead Sciences Scales Back California Expansion, Announces Layoffs

Gilead Sciences, a prominent player in the pharmaceutical industry, has made significant changes to its expansion plans in California, resulting in layoffs and a strategic shift in its biologics operations. The company's decision reflects broader trends in the industry as pharmaceutical giants continue to optimize their operations and adapt to changing market dynamics.

NoahAI News6/16/2025

AstraZeneca's Ultomiris Shows Promise in Rare Post-Transplant Complication

AstraZeneca has unveiled encouraging early results from a phase 3 trial of Ultomiris (ravulizumab) in pediatric patients with thrombotic microangiopathy (TMA) following hematopoietic stem cell transplantation (HSCT). The data, presented at the 2025 European Hematology Association meeting in Milan, Italy, highlights the potential of Ultomiris to address a life-threatening complication that currently lacks targeted treatment options.

NoahAI News6/16/2025

NextCure Expands ADC Portfolio with $745M Deal for Simcere's Phase 1 Drug

NextCure, a biotechnology company focusing on novel cancer immunotherapies, has significantly bolstered its antibody-drug conjugate (ADC) pipeline through a $745 million licensing agreement with Chinese pharmaceutical firm Simcere Zaiming. The deal grants NextCure ex-China rights to SIM0505, a phase 1-stage tumor asset targeting CDH6.

NoahAI News6/16/2025

FDA Resource Constraints Delay Decision on Kalvista's Hereditary Angioedema Drug

The U.S. Food and Drug Administration (FDA) has announced it will miss the approval deadline for Kalvista Therapeutics' experimental drug sebetralstat, citing resource constraints and a heavy workload. This delay marks a significant development in the pharmaceutical industry, highlighting potential challenges faced by regulatory bodies in keeping pace with drug evaluations.

NoahAI News6/16/2025

South Korean Biotech's GLP-1 Drug Shows Promise in MASH Treatment with Added Weight Loss Benefits

D&D Pharmatech, a South Korean biotechnology company, has reported positive results from a clinical trial of its dual GLP-1/glucagon receptor agonist, DD01, in patients with metabolic dysfunction-associated steatohepatitis (MASH). The study demonstrates significant reductions in liver fat and notable weight loss effects, potentially positioning DD01 as a promising candidate in the competitive landscape of MASH treatments.

NoahAI News6/16/2025

Eli Lilly's Amylin Analog Shows Promise in Phase 1 Obesity Trial

Eli Lilly has unveiled promising phase 1 data for its amylin analog eloralintide, positioning the pharmaceutical giant as a strong contender in the increasingly competitive obesity treatment market. The results, shared ahead of the American Diabetes Association conference, have impressed analysts and suggest potential for eloralintide to be combined with Lilly's blockbuster drug Zepbound (tirzepatide) to create a market-leading obesity treatment.

NoahAI News6/16/2025

FDA Delays and Workforce Challenges Impact Drug Approvals

The pharmaceutical industry is facing significant challenges as the U.S. Food and Drug Administration (FDA) grapples with a heavy workload and limited resources, leading to delays in drug approval decisions. Recent developments highlight the ongoing impact of FDA restructuring and layoffs on the drug review process.

NoahAI News6/16/2025

AI Revolutionizes Precision Oncology: A Turning Point in 2025

The pharmaceutical industry is witnessing a transformative era as artificial intelligence (AI) takes center stage in precision oncology. Major players like AstraZeneca and Pfizer are harnessing AI's computational power to revolutionize drug discovery, clinical trial design, and patient care. As we approach 2025, experts anticipate a paradigm shift in how cancer therapies are developed and deployed.

NoahAI News6/16/2025

«1...64 65 66 67 »